| __timestamp | Intra-Cellular Therapies, Inc. | Merus N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 3852327 |
| Thursday, January 1, 2015 | 18187286 | 839656 |
| Friday, January 1, 2016 | 24758063 | 4478145 |
| Sunday, January 1, 2017 | 23666957 | 16432324 |
| Monday, January 1, 2018 | 30099855 | 11890871 |
| Tuesday, January 1, 2019 | 64947625 | 34110000 |
| Wednesday, January 1, 2020 | 186363444 | 35781000 |
| Friday, January 1, 2021 | 272611040 | 40896000 |
| Saturday, January 1, 2022 | 358782000 | 52200000 |
| Sunday, January 1, 2023 | 409864000 | 59836000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing expenses is crucial for success. This chart highlights the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Merus N.V. from 2014 to 2023. Over this period, Intra-Cellular Therapies, Inc. has seen a staggering increase in SG&A expenses, growing nearly 40 times from 2014 to 2023. In contrast, Merus N.V.'s expenses have increased by approximately 15 times, indicating a more conservative growth strategy.
The data reveals that Intra-Cellular Therapies, Inc. experienced a significant surge in expenses starting in 2019, peaking in 2023. This could suggest aggressive expansion or increased operational costs. Meanwhile, Merus N.V. maintained a steadier growth trajectory, with a notable increase in 2023. Understanding these trends provides valuable insights into each company's strategic priorities and financial health.
Breaking Down SG&A Expenses: Johnson & Johnson vs Intra-Cellular Therapies, Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Intra-Cellular Therapies, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Intra-Cellular Therapies, Inc. Trends and Insights
Intra-Cellular Therapies, Inc. and Dr. Reddy's Laboratories Limited: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Corcept Therapeutics Incorporated
Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Alkermes plc vs Merus N.V.
Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and Merus N.V.
Comparing SG&A Expenses: MorphoSys AG vs Merus N.V. Trends and Insights
Comparing SG&A Expenses: Vericel Corporation vs Merus N.V. Trends and Insights
Who Optimizes SG&A Costs Better? Merus N.V. or Amphastar Pharmaceuticals, Inc.